Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

  		Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympto-matic 'watchfull waiting' PCa patients who fail prostate removal & hormone therapy, with no approved drug availble to them. 

Drugs for  therapy-resitant solid cancers & hypoxic conditions 

 Colby's mission is to develop & sell drugs for hypoxia & therapy-resistant tumors
Colby drugs resore therapy-sensitivity or normoxia

About Colby

Biz.Dev. Dir. Alex Zhavoronkov, PhD

Director of Business Development

 

Alex Zhavoronkov, PhD has over ten years of experience in business development, marketing and general management in the information technology and life sciences industries. Prior to joining Colby Pharmaceutical Company as Director of Business Development, Dr. Zhavoronkov had a successful career as Sales Director at ATI Technologies, Inc, President of Mediox, Inc. and Director of Business Development at GTCbio.
He is also a trustee and head of fundraising at the Biogerontology Research Foundation, a UK-based charity organization focused on alleviating suffering in the elderly.

Dr. Zhavoronkov holds a Bachelor of Commerce and Bachelor of Science degrees from Queen’s University, a Master of Science degree in biotechnology from John Hopkins University and a PhD degree in biophysics from Moscow State University.